Select your Country or Region

  • TargetMol | Compound LibraryArgentinaArgentina
  • TargetMol | Compound LibraryAustraliaAustralia
  • TargetMol | Compound LibraryAustriaAustria
  • TargetMol | Compound LibraryBelgiumBelgium
  • TargetMol | Compound LibraryBrazilBrazil
  • TargetMol | Compound LibraryBulgariaBulgaria
  • TargetMol | Compound LibraryCroatiaCroatia
  • TargetMol | Compound LibraryCyprusCyprus
  • TargetMol | Compound LibraryCzechCzech
  • TargetMol | Compound LibraryDenmarkDenmark
  • TargetMol | Compound LibraryEgyptEgypt
  • TargetMol | Compound LibraryEstoniaEstonia
  • TargetMol | Compound LibraryFinlandFinland
  • TargetMol | Compound LibraryFranceFrance
  • TargetMol | Compound LibraryGermanyGermany
  • TargetMol | Compound LibraryGreeceGreece
  • TargetMol | Compound LibraryHong KongHong Kong
  • TargetMol | Compound LibraryHungaryHungary
  • TargetMol | Compound LibraryIcelandIceland
  • TargetMol | Compound LibraryIndiaIndia
  • TargetMol | Compound LibraryIrelandIreland
  • TargetMol | Compound LibraryIsraelIsrael
  • TargetMol | Compound LibraryItalyItaly
  • TargetMol | Compound LibraryJapanJapan
  • TargetMol | Compound LibraryKoreaKorea
  • TargetMol | Compound LibraryLatviaLatvia
  • TargetMol | Compound LibraryLebanonLebanon
  • TargetMol | Compound LibraryMalaysiaMalaysia
  • TargetMol | Compound LibraryMaltaMalta
  • TargetMol | Compound LibraryMoroccoMorocco
  • TargetMol | Compound LibraryNetherlandsNetherlands
  • TargetMol | Compound LibraryNew ZealandNew Zealand
  • TargetMol | Compound LibraryNorwayNorway
  • TargetMol | Compound LibraryPolandPoland
  • TargetMol | Compound LibraryPortugalPortugal
  • TargetMol | Compound LibraryRomaniaRomania
  • TargetMol | Compound LibrarySingaporeSingapore
  • TargetMol | Compound LibrarySlovakiaSlovakia
  • TargetMol | Compound LibrarySloveniaSlovenia
  • TargetMol | Compound LibrarySpainSpain
  • TargetMol | Compound LibrarySwedenSweden
  • TargetMol | Compound LibrarySwitzerlandSwitzerland
  • TargetMol | Compound LibraryTaiwan,ChinaTaiwan,China
  • TargetMol | Compound LibraryThailandThailand
  • TargetMol | Compound LibraryTurkeyTurkey
  • TargetMol | Compound LibraryUnited KingdomUnited Kingdom
  • TargetMol | Compound LibraryUnited StatesUnited States
  • TargetMol | Compound LibraryOther CountriesOther Countries
Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

Rabacfosadine

Rabacfosadine
Contact us for more batch information
Select Batch
Purity:99.43%
ee:100%

Rabacfosadine

Catalog No. T16716Cas No. 859209-74-8
Rabacfosadine (GS-9219) is a novel dual pre-drug of the acyclic nucleotide phosphonate PMEG to tumor lymphocytes for the study of lymphoma.
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Pack SizePriceAvailabilityQuantity
1 mg$158In Stock
5 mg$389In Stock
10 mg$579In Stock
25 mg$928In Stock
50 mg$1,260In Stock
100 mg$1,680In Stock
Bulk & Custom
Add to Cart

Product Introduction

Bioactivity
Description
Rabacfosadine (GS-9219) is a novel dual pre-drug of the acyclic nucleotide phosphonate PMEG to tumor lymphocytes for the study of lymphoma.
In vitro
Rebaarsen inhibits the proliferation of mitogen-stimulated T and B lymphocytes as determined by BrdUrd binding assay (EC50 135 and 42 nM, respectively). GS-9219 showed strong antiproliferative activity against activated lymphocytes and hematopoietic tumor cell lines. Labafaxadine is converted to its active metabolite, PMEG diphosphate, by enzymatic hydrolysis, deamination and phosphorylation in lymphocytes. In this paper, we investigated the ability of rabafaxadine to inhibit the proliferation of activated lymphocytes and hematopoietic tumor cells. To compare the activity of GS-9219 in dividing and non-dividing cells, the activity of Rabacfosadine in these cell populations was assessed using the metabolism-based XTT sodium assay rather than the BrdUrd assay.The results of the XTT assay showed that the EC50 values of Rabacfosadine differed from those in quiescent (EC50=17.2 μM) and proliferating cells (EC50=135 nM). ) in quiescent cells (EC50=17.2 μM) and proliferating cells (EC50=135 nM) with a 127-fold difference in EC50 values. These results suggest that Rabatadine has a great selectivity for actively replicating lymphoblastoid cells [1].
In vivo
Rabatadine has potent single-agent activity in dogs with lymphoma by a mechanism of action different from that of doxorubicin. Dogs are treated alternately with rabafenacin (1.0 mg/kg, i.v., weeks 0, 6, and 12) and doxorubicin (30 mg/m2, i.v., weeks 3, 9, and 15). Dogs that achieved a complete response (CR) were evaluated at monthly follow-up visits. Complete clinicopathologic evaluations were performed every 21 days and remission and adverse events (AEs) were assessed. Acute AEs (occurring within 21 days of the first dose of each drug) were compared between labradine and doxorubicin in 46 dogs with at least 1 dose of each drug [2].
AliasVDC-1101, GS-9219
Chemical Properties
Molecular Weight526.53
FormulaC21H35N8O6P
Cas No.859209-74-8
Storage & Solubility Information
Storage Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Solubility Information
DMSO: 80 mg/mL (151.94 mM)
Solution Preparation Table
DMSO
1mg5mg10mg50mg
1 mM1.8992 mL9.4961 mL18.9923 mL94.9614 mL
5 mM0.3798 mL1.8992 mL3.7985 mL18.9923 mL
10 mM0.1899 mL0.9496 mL1.8992 mL9.4961 mL
20 mM0.0950 mL0.4748 mL0.9496 mL4.7481 mL
50 mM0.0380 mL0.1899 mL0.3798 mL1.8992 mL
100 mM0.0190 mL0.0950 mL0.1899 mL0.9496 mL

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
TargetMol | Animal experimentsFor example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . TargetMol | Animal experiments A total of 10 animals were administered, and the formula you used is 5% TargetMol | reagent DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。
Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSOTargetMol | reagent (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
Preparation method for in vivo formula: Take 50 μL DMSOTargetMol | reagent main solution, add 300 μLPEG300TargetMol | reagent mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2OTargetMol | reagent mix well and clarify
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
%Tween 80
%ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords